In yesterday’s Wall Street session, Dermata Therapeutics Inc. (NASDAQ:DRMA) shares traded at $0.20, up 4.11% from the previous session.
As of this writing, 2 analysts cover Dermata Therapeutics Inc. (NASDAQ:DRMA). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $11.00 and a low of $1.00, we find $6.00. Given the previous closing price of $0.19, this indicates a potential upside of 3057.89 percent. DRMA stock price is now -60.54% away from the 50-day moving average and -71.95% away from the 200-day moving average. The market capitalization of the company currently stands at $2.42M.
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
A total of 2.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DRMA stock. A new stake in Dermata Therapeutics Inc. shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $14,000. JANE STREET GROUP, LLC invested $5,000 in shares of DRMA during the first quarter. In the first quarter, FMR LLC acquired a new stake in Dermata Therapeutics Inc. valued at approximately $2,000. In total, there are 12 active investors with 1.60% ownership of the company’s stock.
Thursday morning saw Dermata Therapeutics Inc. (NASDAQ: DRMA) opened at $0.1863. During the past 12 months, Dermata Therapeutics Inc. has had a low of $0.16 and a high of $2.45. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.00, and a quick ratio of 6.00. The fifty day moving average price for DRMA is $0.5069 and a two-hundred day moving average price translates $0.7130 for the stock.
The latest earnings results from Dermata Therapeutics Inc. (NASDAQ: DRMA) was released for Jun, 2022.
Dermata Therapeutics Inc.(DRMA) Company Profile
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company’s lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.